Onkologie. 2017:11(4):192-195 | DOI: 10.36290/xon.2017.036

Promising treatment options of triple negative breast cancer

Josef Dvořák1, Drahomíra Kordíková1, Katarína Lajbl Večeřová1, Igor Richter2, Jana Hornová1, Aneta Rozsypalová1, Eva Spisarová1, Ludmila Boublíková1, Jitka Abrahámová1
1 Onkologická klinika, 1. LF UK a Thomayerova nemocnice, Praha
2 Oddělení klinické onkologie, Krajská nemocnice Liberec, a. s.

Triple negative breast cancer constitutes a histologically, molecularly and immunologically heterogeneous group of diseases,characterized by lack of α-estrogen, progesteron receptors and HER2 expression. This review presents recent studies of promisingtreatment options of triple negative breast cancer.

Keywords: triple negative breast carcinoma, platinum derivates, olaparib, bevacizumab, eribulin, pembrolizumab

Published: October 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dvořák J, Kordíková D, Lajbl Večeřová K, Richter I, Hornová J, Rozsypalová A, et al.. Promising treatment options of triple negative breast cancer. Onkologie. 2017;11(4):192-195. doi: 10.36290/xon.2017.036.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016; 13(11): 674-690. Go to original source... Go to PubMed...
    2. Pogoda K, Niwinska A, Murawska M, et al. The outcome of special histologic types of triple-negative breast cancer (TNBC). J Clin Oncol 2014; 32(5S) Suppl; Abstract 1122. Go to original source...
    3. Svoboda M, Navrátil J, Fabián P, et al. Triple-negativní karcinom prsu: analýza souboru pacientek diagnostikovaných a/nebo léčených v Masarykově onkologickém ústavu v letech 2004 až 2009. Klin Onkol 2012; 25(3): 188-198. Go to PubMed...
    4. Navrátil J, Fabián P, Palácová M, et al. Triple negativní karcinom prsu. Klin Onkol 2015; 28(6): 405-415. Go to original source... Go to PubMed...
    5. Fornier M, Fumoleau P. The paradox of triple negative breast cancer: novel approaches to treatment. Breast J 2012; 18(1): 41-51. Go to original source... Go to PubMed...
    6. Tesařová P, a kol. Triple negativní karcinom prsu a možnosti jeho léčby. Praha: AT Mediprint s.r.o. 2013: 21 s.
    7. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363(20): 1938-1948. Go to original source... Go to PubMed...
    8. von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; 15(7): 747-756. Go to original source... Go to PubMed...
    9. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384(9938): 164-172. Go to original source... Go to PubMed...
    10. Alba E, Chacon J, Lluch A, et al. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat 2012; 136(2): 487-493. Go to original source... Go to PubMed...
    11. Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33(1): 13-21. Go to original source... Go to PubMed...
    12. Gluz O, Nitz U, Liedtke C, et al. Comparison of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. Presented at: 38th annual San Antonio breast cancer symposium. San Antonio; 2015. Abstract S6-07. Go to original source...
    13. http://clinicaltrials.gov
    14. Robson ME, Im SA, Senkus E, et al. OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). J Clin Oncol 2017; 35 (18) Suppl: Abstract LBA4. Go to original source...
    15. Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27(30): 4966-4972. Go to original source... Go to PubMed...
    16. Miles DW, Diéras V, Cortés J, et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013; 24(11): 2773-2780. Go to original source... Go to PubMed...
    17. Bell R, Brown J, Parmar M, et al. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Ann Oncol 2017; 28(4): 754-760. Go to original source... Go to PubMed...
    18. Ma X, Wang X, Huang J, et al. Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis. PLoS One 2016; 11 (8): e0160148. doi: 10.1371/journal.pone.0160148.eCollection 2016. Go to original source... Go to PubMed...
    19. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011; 377: 914-923. Go to original source... Go to PubMed...
    20. Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2015; 33(6): 594-601. Go to original source... Go to PubMed...
    21. Twelves C, Cortes J, Vahdat L, et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 2014; 148(3): 553-561. Go to original source... Go to PubMed...
    22. Gonzalez-Angulo AM, Akcakanat A, Liu S, et al. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Ann Oncol 2014; 25(6): 1122-1127. Go to original source... Go to PubMed...
    23. Singh J, Novik Y, Stein S, et al. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res 2014; 16 (2): R32. doi: 10.1186/bcr3634. Go to original source... Go to PubMed...
    24. Baselga J, Gómez P, Greil R, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013; 31(20): 2586-2592. Go to original source... Go to PubMed...
    25. Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol 2016; 34(21): 2460-2467. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.